Open Nav

GLAdiator Biosciences, Inc.

  • Terry Hermiston, GLAdiator Biosciences, Inc

To introduce, socialize and secure investors for the GLAdiator Biosciences platform

  • Date:Wednesday, October 17
  • Time:3:45 PM - 4:00 PM
  • Room:Elizabethan D
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:GLAdiator Biosciences has developed a proprietary delivery platform for the safer, more selective and effective treatment of cancer. Formed in 2018, the Company’s technology is based on a 2 year collaboration between Bayer HealthCare and Stanford University. The platform exploits a naturally occurring protein domain associated with coagulation factors known as gamma-carboxyglutamic acid (GLA) to selectively target and internalize into cancer through the recognition of the phospholipid phosphatidylserine (PS) that is expressed on the surface of cancer cells. Healthy, normal cells do not expose PS on their cell surface. This targeting selectivity of GLA is supported by pre-clinical in vitro and in vivo studies including biodistribution profiling in healthy animals. The Company is currently screening both traditional (small molecules, biologics) and non-traditional (e.g. nucleotides) therapeutic payloads to identify one or more clinical candidates in the next 18-24 months.
  • Company Website:Stealth mode
  • Company HQ City:Mill Valley
  • Company HQ Country:United States
  • Company HQ State:California                  
  • CEO/Top Company Official:Terry Hermiston
  • Year Founded:2018
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development :Screening to identify a clinical candidate in 18-24 months
  • Development Phase of Primary Product:Discovery
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :3 or more
  • Additional Information/Comments:The Company’s novel delivery platform addresses existing challenges to antibody drug conjugates, cell penetrating peptides and sting agonists - namely poor targeting and inefficient transport into tumor cells, leading to off target toxicity and suboptimal dosing. The targeting specificity for PS and subsequent internalization into the cell affords the potential to develop more effective and targeted therapies, including the targeted delivery of dinucleotides. GLAdiator’s management team is composed of seasoned drug development scientists from Bayer HealthCare. The Company’s scientific and medical advisors include world class scientists and clinicians in Oncology. The Company recently concluded the acquisition of its technology from Bayer and closed the initial tranche of its seed round. We believe that GLAdiator Biosciences offers a compelling opportunity for investment and partnering and we look forward to being selected as a presenting company.
  • Previous and Current Investors:Friends and Family
  • Size of Last Investment Round:$1M
  • Total Amount Raised to Date, In All Rounds:$1M seed round
Terry Hermiston
GLAdiator Biosciences, Inc